onvansertib
onvansertib: developed by 1 company · 4 clinical trials tracked.
onvansertib evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could onvansertib → CRDF affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Cardiff Oncology, Inc. (CRDF) Metastatic Colorectal Cancer; Recurrent Chronic Myelomonocyt… | Phase 2 |
Clinical Trials (4)
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation
Primary endpoint: Objective Response Rate (ORR)
Phase 1 Study to Determine the Safety and Efficacy of Onvansertib, A Novel, Oral, PLK1 Inhibitor in Patients With Proliferative Chronic Myelomonocytic Leukemia (CMML) and Myelodysplastic Syndrome/MPN Overlap Neoplasms Relapsed/Refractory or Intolerant to Available Therapies
Primary endpoint: Incidence of adverse events
A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
Primary endpoint: Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baseline
A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS Mutation
Primary endpoint: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)
Frequently asked questions
Who is developing onvansertib?
onvansertib is being developed by Cardiff Oncology, Inc..
How many clinical trials involve onvansertib?
BioSniper tracks 4 clinical trials involving onvansertib.